Recent articles

Update – November 22, 2024 This morning, Lexicon Pharmaceuticals, Inc. (Lexicon) announced they received a “deficiencies preclude discussion” letter from the FDA regarding this drug application. The FDA is not approving sotagliflozin for use in glucose control in people with T1D and CKD and there will be no further discussion in regards to this application.  […]

A novel immune therapy called tegoprubart made by Eledon Pharmaceuticals and being tested in kidney transplant patients has the potential to help beta cell transplants survive in people with type 1 diabetes (T1D) with fewer side effects. The first data from this Breakthrough T1D-funded study suggests it does. The study was presented at the 5th […]

At the 2024 International Society for Pediatric and Adolescent Diabetes (ISPAD) Conference in Lisbon, Portugal, the world’s leading diabetes researchers, academics, and members of industry gathered to share the latest and greatest in diabetes research. Breakthrough T1D leaders and many of our funded researchers and collaborators were on hand —for ISPAD’s 50th birthday—to share new […]

It’s early October, which means the Nobel Prizes are being awarded in several categories. These prestigious awards recognize outstanding contributions in Peace, Literature, Physics, Chemistry, Physiology or Medicine, and Economic Sciences. They go to the best and brightest people with the best and brightest ideas. This year, the prizes recognize work that is, in several […]

A new study published in Cell and summarized in Nature has shown positive results using stem cell-derived islets to restore insulin production in a patient with type 1 diabetes (T1D). These results add to the mounting evidence that stem cell-derived islets can provide benefits to people with T1D. The study, conducted by investigators in Beijing, […]

Press releases

Read the latest press releases and statements from Breakthrough T1D.

Get the latest in T1D news updates

Sign up for Insider News to receive breaking news updates from Breakthrough T1D.

  • This field is for validation purposes and should be left unchanged.